Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-Fc) (BSCFV-117)

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD37 specificity or anti-CD64 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD37 & CD64

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL)

Targets

Target 1

CD37

Gene ID

951

UniProt ID

P11049

Alternative Names

CD37; CD37 molecule; GP52-40; TSPAN26; leukocyte antigen CD37; tspan-26; tetraspanin-26; leukocyte surface antigen CD37; cell differentiation antigen 37

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-Fc) (BSCFV-117). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-117)

Specifications

Targets

Customer Reviews and Q&As